|Dr. Yakov N. Kogan Ph.D., MBA||Chief Exec. Officer and Interim Principal Financial Officer||287.47k||N/A||1973|
|Dr. Langdon L. Miller M.D.||Pres and Chief Medical Officer||193.57k||N/A||1954|
|Dr. Andrei V. Gudkov Ph.D., D.Sci.||Chief Scientific Officer||N/A||N/A||1956|
|Dr. Ann Lenich Hards Ph.D.||Exec. VP of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Andrei Purmal Ph.D.||VP of Chemistry||N/A||N/A||N/A|
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Cleveland BioLabs, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.